Oversold Conditions For Dendreon (DNDN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Thursday, shares of Dendreon Corp ( DNDN) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $4.30 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 46.2. A bullish investor could look at DNDN's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DNDN shares:

Find out what 9 other oversold stocks you need to know about »

Dendreon Corp 1 Year Performance Chart

Looking at the chart above, DNDN's low point in its 52 week range is $3.69 per share, with $12.21 as the 52 week high point — that compares with a last trade of $4.33.

According to the ETF Finder at ETF Channel, DNDN makes up 1.70% of the SPDR S&P Biotech ETF (XBI) which is trading lower by about 0.9% on the day Thursday.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes